Multiple Myeloma Conference Coverage EHA 2020 Highlights

The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?

Maria Victoria Mateos, MD, PhD Aptitude Health 2020 multiple myeloma

Faculty Chair(s)

Maria Victoria Mateos, MD, PhD

University of Salamanca, Salamanca, Spain

Download Meeting Agenda

This agenda is preliminary. Discussion topics may change depending on final EHA abstract selection. To download the draft agenda for this meeting:

Report Topics and Discussion Points

Smoldering Myeloma

  • Is there a uniform definition of smoldering myeloma? Are you currently treating smoldering myeloma outside of clinical trials? How are you treating?
  • What factors influence your decision regarding which patients with smoldering myeloma to treat?
  • Risk factors that identify progression to MM
  • Treatment of high-risk smoldering myeloma – how best can we risk-stratify?
  • How to risk-stratify into low, intermediate and high risk?

First-Line (1): Transplant-Ineligible Multiple Myeloma

  • How do we define transplant ineligibility? Are there uniform criteria that we all can agree on?
  • What is your current standard of care in transplant-ineligible patients?
  • What are the relative benefits and limitations of the different induction regimens?
  • How will the emerging data impact your selection of induction regimen for your transplant-ineligible patients?
  • Maintenance therapy in transplant-ineligible patients – what agent to use, if any; for how long; and how do we monitor?

First-Line (2): Induction in Transplant-Eligible Multiple Myeloma

  • Do data support use of monoclonal antibodies in induction therapy? If so, which regimens are most appropriate, for which patient populations?
  • Are you using proteasome inhibitors as part of your induction regimen?
  • Which proteasome inhibitors do you use? At what dose/schedule?
  • Which regimen is best to use in induction for transplant-eligible patients?
  • How have you been treating transplant-eligible high-risk patients, and how will these data impact your treatment of high-risk patients?
  • How do we risk-stratify?

First-Line (3): Assessing Prognosis

  • Beyond MRD, what prognostic factors do you use?
  • Will the data with PET-CT at diagnosis and follow-up influence you?
  • Do you evaluate MRD outside of clinical trials? If you do, how do you use this information?

Relapsed/Refractory: Novel Therapies

  • On the basis of current data, what setting(s) and combination(s) are optimal for use of
    • Small molecules (venetoclax, selinexor)?
    • Monoclonal antibodies (belantamab mafodotin)?
  • What are the limitations of these novel therapies?
  • Which patients would you consider for treatment with small molecules or monoclonal antibodies?
  • What would the competitors be for these new strategies in the relapsed/refractory setting?

Confirmed Faculty

Irene Ghobrial, MD
Harvard Medical School, Dana-Farber Cancer Center, Boston, MA, US

Niels van de Donk, MD, PhD
Amsterdam University Medical Center, Amsterdam, the Netherlands

Mohamad Mohty, MD
Saint-Antoine Hospital and Sorbonne University, Paris, France

Sagar Lonial, MD, FACP
Emory University School of Medicine, Atlanta, GA, US

Mario Boccadoro, MD
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torina, Italy

Explore Available and Upcoming Insight Reports

View Reports